O. Kloke

1.3k total citations
54 papers, 939 citations indexed

About

O. Kloke is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, O. Kloke has authored 54 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Oncology and 21 papers in Genetics. Recurrent topics in O. Kloke's work include Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Eosinophilic Disorders and Syndromes (12 papers). O. Kloke is often cited by papers focused on Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Eosinophilic Disorders and Syndromes (12 papers). O. Kloke collaborates with scholars based in Germany, United States and Sweden. O. Kloke's co-authors include N. Niederle, Bertram Opalka, S. Seeber, M. Nagel‐Hiemke, U. Wandl, R. Becher, Dieter May, E. Kreuzfelder, DW Beelen and AH Elmaagacli and has published in prestigious journals such as Blood, British Journal of Cancer and Annals of Oncology.

In The Last Decade

O. Kloke

53 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Kloke Germany 17 440 289 266 264 192 54 939
J Odriozola Spain 15 667 1.5× 269 0.9× 192 0.7× 77 0.3× 180 0.9× 46 914
Joel Kremer United States 7 534 1.2× 306 1.1× 214 0.8× 1.1k 4.0× 464 2.4× 12 1.5k
Chikako Ohwada Japan 16 359 0.8× 149 0.5× 122 0.5× 74 0.3× 73 0.4× 63 691
Edit Drescher United States 13 463 1.1× 211 0.7× 301 1.1× 922 3.5× 486 2.5× 35 1.3k
Yvonne Sherrer United States 7 391 0.9× 218 0.8× 116 0.4× 921 3.5× 441 2.3× 11 1.3k
Bouchra Asli France 15 358 0.8× 256 0.9× 125 0.5× 259 1.0× 206 1.1× 30 1.1k
J. Box United States 7 356 0.8× 217 0.8× 101 0.4× 763 2.9× 367 1.9× 10 1.1k
B. Combe France 13 247 0.6× 151 0.5× 77 0.3× 638 2.4× 301 1.6× 22 959
Katsumichi Fujimaki Japan 19 419 1.0× 254 0.9× 330 1.2× 50 0.2× 153 0.8× 85 1.1k
Edward Flynn United Kingdom 17 231 0.5× 89 0.3× 94 0.4× 363 1.4× 453 2.4× 25 839

Countries citing papers authored by O. Kloke

Since Specialization
Citations

This map shows the geographic impact of O. Kloke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Kloke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Kloke more than expected).

Fields of papers citing papers by O. Kloke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Kloke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Kloke. The network helps show where O. Kloke may publish in the future.

Co-authorship network of co-authors of O. Kloke

This figure shows the co-authorship network connecting the top 25 collaborators of O. Kloke. A scholar is included among the top collaborators of O. Kloke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Kloke. O. Kloke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simonsson, Bengt, O. Kloke, & R. Stahel. (2005). ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). Annals of Oncology. 16. i52–i53. 10 indexed citations
2.
Kloke, O., et al.. (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Annals of Oncology. 16. i45–i47. 19 indexed citations
3.
Jost, L.M., O. Kloke, & Rolf A. Stahel. (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. Annals of Oncology. 16(9). i58–i59. 17 indexed citations
4.
Kloke, O., U. Klaassen, C. Oberhoff, et al.. (1999). Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Breast Cancer Research and Treatment. 55(1). 51–59. 31 indexed citations
5.
Siebert, Reiner, Christoph Willers, Alexander Fosså, et al.. (1996). Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines. Leukemia Research. 20(2). 197–200. 5 indexed citations
6.
Kloke, O., et al.. (1996). Prognostic impact of interferon alpha‐induced cytogenetic remission in chronic myelogenous leukaemia: long‐term follow‐up. European Journal Of Haematology. 56(1-2). 78–81. 7 indexed citations
7.
Thiele, J., Hans Michael Kvasnicka, N. Niederle, et al.. (1995). The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML — A comparative morphometric study on sequential trephine biopsies. Annals of Hematology. 70(3). 121–128. 17 indexed citations
8.
Niederle, N., et al.. (1993). Long-Term Treatment of Chronic Myelogenous Leukemia with Different Interferons: Results from Three Studies. Leukemia & lymphoma. 9(1-2). 111–119. 24 indexed citations
9.
Kloke, O., et al.. (1992). Opposite Sensitivity to the Antiproliferative Action of Interferon-α and Granulocyte-Macrophage Colony-Stimulating Factor in Monoblastic U937 Cells. Journal of Interferon Research. 12(5). 369–376. 4 indexed citations
10.
Moritz, Thomas, O. Kloke, M. Nagel‐Hiemke, et al.. (1992). Tumor necrosis factor α modifies resistance to interferon α in vivo: First clinical data. Cancer Immunology Immunotherapy. 35(5). 342–346. 6 indexed citations
11.
Nagel‐Hiemke, M., Dieter May, E. Kreuzfelder, et al.. (1992). Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clinical Immunology and Immunopathology. 65(1). 70–74. 122 indexed citations
12.
Becher, R., O. Kloke, Dieter May, et al.. (1991). Ifosfamide. Methotrexate and 5-Fluorouracil for Pretreated Advanced Breast Cancer. Oncology. 48(6). 459–463. 2 indexed citations
13.
Doberauer, C., et al.. (1991). Treatment of Metastatic Carcinoid Tumors and the Carcinoid Syndrome with Recombinant interferon Alpha. Acta Oncologica. 30(5). 603–605. 15 indexed citations
14.
15.
16.
Kloke, O., et al.. (1990). Treatment of chronic myelogenous leukemia with interferons alpha and gamma. Annals of Hematology. 61(1). 45–46. 6 indexed citations
17.
Wandl, U., Dieter May, O. Kloke, et al.. (1990). DNA-flow cytometry studies in blood and marrow cells from chronic myelogenous leukemia patients treated with interferon alpha-2b. Leukemia Research. 14(10). 905–908. 3 indexed citations
18.
Becher, R., et al.. (1989). Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma. British Journal of Cancer. 59(6). 948–948. 3 indexed citations
19.
Kloke, O., Dieter May, U. Wandl, & N. Niederle. (1988). Zur Dosierung von Interferon alpha in der Induktions und Erhaltungstherapie der Haarzellenleukämie. Oncology Research and Treatment. 11(2). 41–45. 3 indexed citations
20.
Doberauer, C., et al.. (1987). Zur Behandlung des metastasierten Karzinoids von Ileum und Caecum mit rekombinantem Interferon alpha-2b. Oncology Research and Treatment. 10(6). 340–344. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Odriozola Breakdown of academic impact, for papers by Joel Kremer Breakdown of academic impact, for papers by Chikako Ohwada Breakdown of academic impact, for papers by Edit Drescher Breakdown of academic impact, for papers by Yvonne Sherrer Breakdown of academic impact, for papers by Bouchra Asli Breakdown of academic impact, for papers by J. Box Breakdown of academic impact, for papers by B. Combe Breakdown of academic impact, for papers by Katsumichi Fujimaki Breakdown of academic impact, for papers by Edward Flynn
Rankless by CCL
2026